<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="347534">
  <stage>Registered</stage>
  <submitdate>3/10/2011</submitdate>
  <approvaldate>10/10/2011</approvaldate>
  <actrnumber>ACTRN12611001057976</actrnumber>
  <trial_identification>
    <studytitle>The effects of nasal continuous positive airway pressure on cardiac function in (i) premature infants with established lung disease and (ii) premature infants with minimal lung disease.</studytitle>
    <scientifictitle>In preterm infants with a corrected gestational age of 28-34 weeks, do levels of nasal CPAP of 4 or 8 cm of water affect right ventricular cardiac output?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>effect of nasal CPAP on right ventricular output</healthcondition>
    <healthcondition>in premature infants with significant lung disease and minimal lung disease</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2>Normal development and function of the cardiovascular system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Complications of newborn</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>nasal continuous positive airway pressure of 4, 6 and 8 centimeter of water for 15 minutes each in randomized order. There will be 5-10 minutes before changing to the next CPAP level to allow for echocardiographic assessment.</interventions>
    <comparator>each infants is his/her own control as different levels of nasal CPAP are compared</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>right ventricular output, assessed by echocardiography</outcome>
      <timepoint>15 minutes after each change in nCPAP level</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>left ventricular output, assessed by echocardiography</outcome>
      <timepoint>15 minutes after each change in nCPAP level</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Premature infants with a corrected gestational age of 28-34 weeks, admitted to the Neonatal Intensive and Special Care and treated with nasal CPAP.</inclusivecriteria>
    <inclusiveminage>28</inclusiveminage>
    <inclusiveminagetype>Weeks</inclusiveminagetype>
    <inclusivemaxage>34</inclusivemaxage>
    <inclusivemaxagetype>Weeks</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Infants with sepsis, organ failure, necrotizing enterocolitis, seizures, or identified by the clinical team to be too sick to participate in the study will be excluded.
Infants will be excluded if they have congenital heart disease including a haemodynamically significant patent ductus arteriosus (PDA), atrial septal defect (ASD)/persistent foramen ovale (PFO) and/or ventricular septal defect (VSD). Infants will also be excluded if they are treated with fractional inspired oxygen (FiO2) of more than 40%, and/or treated with a PEEP higher than 7 cmH2O, or nasal intermittent mandatory ventilation (nIMV).</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>1/11/2011</anticipatedstartdate>
    <actualstartdate>6/12/2011</actualstartdate>
    <anticipatedenddate />
    <actualenddate>20/03/2013</actualenddate>
    <samplesize>68</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up complete</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Royal Women's Hospital - Parkville</hospital>
    <hospital>Monash Medical Centre - Clayton campus - Clayton</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Royal Women's Hospital</primarysponsorname>
    <primarysponsoraddress>CNR Grattan Street and Flemington Rd
Parkville, Victoria 3052</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>n/a</fundingname>
      <fundingaddress>n/a</fundingaddress>
      <fundingcountry />
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>n/a</sponsorname>
      <sponsoraddress>n/a</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The aim of the study is to determine changes in blood flow in the heart associated with low or high air pressures given with the nasal prong breathing support to the prematurely born infant. Research studies have shown that nasal CPAP can influence the way the blood flows in premature infants.  
We want to find out if the CPAP machine affects the function of the heart and the blood flow to the lungs. So that we can learn what is the most appropriate level of CPAP for infants with different types of lung disease that provides respiratory support with least affect on heart function.</summary>
    <trialwebsite />
    <publication>The effects of nasal continuous positive airway pressure on cardiac function in premature infants with minimal lung disease: a crossover randomized trial.
Beker F, Rogerson SR, Hooper SB, Wong C, Davis PG.
J Pediatr. 2014 Apr;164(4):726-9</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>5/10/2011</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Dr Sheryle Rogerson</name>
      <address>The Women's Hospital
Cnr Grattan Street/Flemington Rd
Parkville, Vic 3052</address>
      <phone>+61 3 8345 2000</phone>
      <fax />
      <email>sheryle.rogerson@thewomens.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Dr Sheryle Rogerson</name>
      <address>The Women's Hospital
Cnr Grattan Street/Flemington Rd
PArkville, Vic 3052</address>
      <phone>+61 3 83452000</phone>
      <fax>+61 3 8345 3789</fax>
      <email>sheryle.rogerson@thewomens.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Sheryle Rogerson</name>
      <address>The Women's Hospital Cnr Grattan Street/Flemington Rd PArkville, Vic 3052</address>
      <phone>+61 3 83452000</phone>
      <fax />
      <email>sheryle.rogerson@thewomens.org.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>